CLVT•prnewswire•
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Summary
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 6, 2026 by prnewswire